#Canada #Montreal #Replicor #HBV #HDV

Replicor's Compassionate Access Program for HBV/HDV

In a groundbreaking development, Replicor Inc. has published significant findings from its first global compassionate access program in the respected Journal of Hepatology. This initiative, led by Dr. Marc Bourlière in France, involved the administration of REP 2139-Mg, a promising treatment aimed at patients battling chronic HBV (Hepatitis B Virus) and HDV (Hepatitis D Virus) infections, particularly those who had exhausted other therapeutic options like bulevirtide and lonafarnib.

The compassionate access program engaged 33 participants across 16 different sites in 8 countries, marking a significant collective effort to address this challenging health issue. The study highlighted several key outcomes:

• - Safety and Efficacy: REP 2139-Mg showcased an exceptional safety profile even among patients with severe liver conditions, including cirrhosis and decompensated cirrhosis. This aspect is crucial given the vulnerability of this patient demographic.
• - Symptom Reversal: Remarkably, rapid improvements were observed in patients' symptoms related to liver decompensation, indicating the treatment's potential to restore liver function effectively.
• - Cure Rates: The results showed impressive rates of HDV cure and functional HBV cure, showcasing the treatment's robustness against these challenging viruses. Notably, some patients were able to achieve viral elimination from their livers after as little as 10 weeks of treatment.

Dr. Andrew Vaillant, the Chief Scientific Officer of Replicor, expressed optimism regarding the findings, stating, "REP 2139 is a unique bifunctional agent that not only directly targets HDV replication but also addresses subviral particle assembly. The results reaffirm the excellent safety and efficacy of REP 2139-Mg, even in the much more at-risk population of patients with decompensated cirrhosis. These findings pave the way for upcoming Phase IIA trials in Europe, which could further validate our approach."

Replicor has firmly positioned itself as a frontrunner in the biopharmaceutical industry, particularly concerning the advancement of therapies for HBV and HDV. With its extensive clinical data, the company remains dedicated to accelerating effective treatments for individuals grappling with these infections, which present significant public health challenges globally.

The findings from the compassionate access program not only rejuvenate hope for patients but also underscore the urgent need for effective therapies in the realm of viral hepatitis. With the studies continuing to yield positive outcomes, stakeholders in the healthcare community now look forward to further trials and potential market availability of REP 2139-Mg, heralding a new era in the fight against HBV and HDV.

For more information about Replicor and its pioneering treatments, visit their website at www.replicor.com.